首页|EAU 2024热点速递:肌层浸润性膀胱癌的临床进展

EAU 2024热点速递:肌层浸润性膀胱癌的临床进展

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
2024年欧洲泌尿外科协会(EAU)年会于4月5日-8日在法国巴黎召开,展示了全球泌尿外科领域的最新进展.肌层浸润性膀胱癌(muscle-invasive bladder cancer,MIBC)的临床进展主要集中在新辅助免疫治疗与新辅助化疗联合免疫治疗、根治性膀胱切除术中淋巴结清扫术的范围、转移性膀胱癌的治疗进展等3个方面,本文就相关内容作简要介绍.
Highlights from EAU 2024:the clinical advances in muscle-invasive bladder cancer
The Annual European Association of Urology(EAU)Congress was held in Paris,France,from A-pril 5th to 8th,2024,showing the latest developments in the field of urology worldwide.The clinical advances in muscle-invasive bladder cancer(MIBC)mainly focus on three aspects:role of neoadjuvant immunotherapy and chemo-immunotherapy,extent of lymphadectomy in radical cystectomy,and the treatment progress in metastatic bladder cancer.This article provides a brief introduction to the relevant contents.

muscle-invasive bladder cancerneoadjuvant therapyimmunotherapycombination therapy

王淼、章小平

展开 >

华中科技大学同济医学院附属协和医院泌尿外科(武汉,430022)

肌层浸润性膀胱癌 新辅助治疗 免疫治疗 联合治疗

2024

10.13201/j.issn.1001-1420.2024.06.017

临床泌尿外科杂志
华中科技大学同济医学院附属协和医院 同济医院

临床泌尿外科杂志

CSTPCD
影响因子：0.734
ISSN：1001-1420
年,卷(期)：2024.39(6)
  • 1
  • 17